Floatz logo

Polyiclc

Metastatic Castration-resistant Prostate Cancer

Parker Institute for Cancer ImmunotherapyPhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

111 Active assets in the Metastatic Castration-resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
Abiraterone Acetate
Mayo Clinic
Phase 4BB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB
CABAZITAXEL
AstraZeneca
Phase 4BB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
BioNTech SE
Phase 4BB
Enzalutamide
AstraZeneca
Phase 4BB

View all 50 →

Same molecule, other indications

Polyiclc is also rated in:

Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
B
Indicative ·
63 / 100
View asset →
melanomaDormant
B
Indicative ·
63 / 100
View asset →
ocular melanomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →